Aptinyx Inc (NASDAQ:APTX) Expected to Announce Quarterly Sales of $860,000.00

Wall Street analysts predict that Aptinyx Inc (NASDAQ:APTX) will announce $860,000.00 in sales for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Aptinyx’s earnings, with the lowest sales estimate coming in at $800,000.00 and the highest estimate coming in at $900,000.00. Aptinyx reported sales of $930,000.00 during the same quarter last year, which would suggest a negative year over year growth rate of 7.5%. The company is expected to announce its next earnings results on Monday, August 10th.

According to Zacks, analysts expect that Aptinyx will report full-year sales of $2.29 million for the current financial year, with estimates ranging from $1.70 million to $3.27 million. For the next financial year, analysts anticipate that the firm will post sales of $0.00. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Aptinyx.

Aptinyx (NASDAQ:APTX) last announced its earnings results on Thursday, May 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.01). Aptinyx had a negative return on equity of 47.99% and a negative net margin of 1,540.42%. The company had revenue of $0.82 million for the quarter, compared to the consensus estimate of $0.91 million.

Several equities research analysts have issued reports on APTX shares. Zacks Investment Research lowered shares of Aptinyx from a “buy” rating to a “hold” rating in a report on Tuesday, June 2nd. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Aptinyx in a research note on Thursday, June 18th. Finally, William Blair began coverage on shares of Aptinyx in a research note on Thursday, May 7th. They set an “outperform” rating for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. Aptinyx currently has an average rating of “Buy” and a consensus target price of $5.42.

APTX traded down $0.32 on Monday, hitting $3.93. 4,198,315 shares of the stock traded hands, compared to its average volume of 327,218. The business has a fifty day moving average price of $3.92 and a two-hundred day moving average price of $3.39. The firm has a market capitalization of $194.04 million, a PE ratio of -2.54 and a beta of 1.46. Aptinyx has a 52 week low of $1.60 and a 52 week high of $5.25.

Institutional investors have recently bought and sold shares of the stock. Acadian Asset Management LLC raised its position in shares of Aptinyx by 75.5% during the 1st quarter. Acadian Asset Management LLC now owns 197,580 shares of the company’s stock valued at $427,000 after acquiring an additional 84,981 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in Aptinyx in the first quarter valued at about $89,000. BlackRock Inc. boosted its holdings in Aptinyx by 15.0% during the first quarter. BlackRock Inc. now owns 426,294 shares of the company’s stock worth $922,000 after buying an additional 55,482 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its position in shares of Aptinyx by 121.1% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 186,831 shares of the company’s stock worth $639,000 after buying an additional 102,332 shares during the period. Finally, Orbimed Advisors LLC grew its position in shares of Aptinyx by 712.7% during the 1st quarter. Orbimed Advisors LLC now owns 1,162,108 shares of the company’s stock worth $2,510,000 after buying an additional 1,019,108 shares during the period. Institutional investors and hedge funds own 56.64% of the company’s stock.

About Aptinyx

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

Featured Story: Cost of Debt

Get a free copy of the Zacks research report on Aptinyx (APTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptinyx (NASDAQ:APTX)

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.